Clinical Trials Browser

INDUSTRY × Leukemia, Prolymphocytic, T-Cell × ibrutinib × Clear all

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2 Completed

14 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell